Oncotelic Therapeutics Inc
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, w… Read more
Oncotelic Therapeutics Inc (OTLC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.038x
Based on the latest financial reports, Oncotelic Therapeutics Inc (OTLC) has a cash flow conversion efficiency ratio of -0.038x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-307.02K) by net assets ($8.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncotelic Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Oncotelic Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oncotelic Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncotelic Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KPM TECH Co. Ltd
KQ:042040
|
0.241x |
|
Precise Biometrics AB (publ)
PINK:PRBCF
|
0.015x |
|
Trimitra Prawara Goldland Tbk Pt
JK:ATAP
|
0.014x |
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
-0.051x |
|
Korea SE Corp
KQ:101670
|
-0.024x |
|
S.A.L. Steel Limited
NSE:SALSTEEL
|
0.289x |
|
Champion Technology Holdings Ltd
PINK:CPIHF
|
-0.145x |
|
FM Global Logistics Holdings Bhd
KLSE:7210
|
0.028x |
Annual Cash Flow Conversion Efficiency for Oncotelic Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Oncotelic Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.48 Million | $-740.27K | -0.099x | +12.98% |
| 2023-12-31 | $11.61 Million | $-1.32 Million | -0.114x | -50.33% |
| 2022-12-31 | $19.19 Million | $-1.45 Million | -0.076x | +86.08% |
| 2021-12-31 | $8.16 Million | $-4.43 Million | -0.544x | -141.25% |
| 2020-12-31 | $12.48 Million | $-2.81 Million | -0.225x | -66.97% |
| 2019-12-31 | $16.90 Million | $-2.28 Million | -0.135x | -120.27% |
| 2018-12-31 | $-362.00K | $-240.98K | 0.666x | -77.56% |
| 2017-12-31 | $-477.00K | $-1.42 Million | 2.966x | -- |